Baculovirus and vaccinia virus vectors were used to express the small (S) and medium (M) genome segments of Hantaan virus. Expression of the complete S or M segments yielded proteins electrophoretically indistinguishable from Hantaan virus nucleocapsid protein or envelope glycoproteins (G1 and G2), and expression of portions of the M segment, encoding either Gl or G2 alone, similarly yielded proteins which closely resembled authentic Hantaan virus proteins. The expressed envelope proteins retained. all antigenic sites defined by a panel of monoclonal antibodies to Hantaan virus Gl and G2 and elicited antibodies in animals which reacted with authentic viral proteins. A Hantaan virus infectivity challenge model in hamsters was used to assay induction of protective immunity by the recombinant-expressed proteins. Recombinants expressing both Gl and G2 induced higher titer antibody responses than those expressing only G1 or G2 and protected most animals from infection with Hantaan virus. Baculovirus recombinants expressing only nucleocapsid protein also appeared to protect some animals from challenge. Passively transferred neutralizing monoclonal antibodies similarly prevented infection, suggesting that an antibody response alone is sufficient for immunity to Hantaan virus.
Hantaan virus, the etiologic agent of Korean hemorrhagic fever, is the prototype of the Hantavirus genus of the Bunyaviridae family. Korean hemorrhagic fever and clinically similar diseases, collectively termed hemorrhagic fever with renal syndrome (HFRS), pose a significant health threat in much of Asia and parts of Europe and Scandinavia. In the People's Republic of China, an estimated 50,000 to 100,000 cases occur annually, with mortality rates reported to be 5 to 20% in various provinces (6, 23) . A vaccine for HFRS is not yet available, although inactivated Hantaan virus-infected mouse brain or rat brain preparations have been tested in humans in North Korea and South Korea (7, 26 ; D. J. Suh, J. W. Song, and H. W. Lee, Virus Information Exchg. Newsl. 6:131, 1989 ). Inactivated tissue-culture-grown Hantaan virus vaccines are under development and testing in Japan and China (25; U.-X. Yu and Z.-Y. Zhe, Virus Information Exchg. Newsl. 6:131, 1989 ). Since Hantaan virus was isolated from the lungs of the Korean striped field mouse, Apodemus agrarius corea, by Lee et al. in 1978 (9) , vaccine development efforts have been hampered by difficulties in virus propagation in a number of cell lines, the slow and low-titer replication of virus in cultured cells, the necessity for a containment laboratory for routine studies with infectious virus, and the absence of an animal model for testing the efficacy of potential immunogenic preparations. For vaccine development studies, we attempted to circumvent some of the problems associated with the use of authentic Hantaan virus by using baculovirus and vaccinia virus recombinants expressing the structural proteins of Hantaan virus.
Like other viruses in the Bunyaviridae family, Hantaan virus has a three-segmented, single-stranded RNA genome whose segments are designated as large (L), medium (M) , and small (S) (15, 17) . The S genome segment encodes the viral nucleocapsid protein (N) in the virus-complementary sense RNA, and the M genome segment encodes the enve-* Corresponding author.
lope glycoproteins Gl and G2 in a single, continuous open reading frame, also in the virus-complementary sense RNA. Unlike viruses in other genera of the Bunyaviridae, neither the S nor the M segments of Hantaan virus appears to encode additional nonstructural polypeptides (19, 21) . The envelope glycoproteins are presumed to be the major elements involved in induction of immunity to Hantaan virus because monoclonal antibodies (MAb) to Gi and G2, but not to N, have been found to neutralize viral infectivity in vitro (1, 5) . The importance of the humoral response for protection against infection was demonstrated with rats by passive transfer of immune sera and subsequent challenge with the hantavirus Sapporo rat (SR-11) virus (27) . A cell-mediated immune response to Hantaan virus has also been implicated in protection; however, the actual importance and protein specificity of the response have not been resolved (2, 3) .
To investigate the potential efficacy of a recombinant vaccine for HFRS, we analyzed the antigenicity and immunogenicity of expressed Hantaan proteins and developed an animal model to estimate protective immunity. To evaluate the components of a vaccine that might be important for protection, we tested recombinant viruses that expressed the complete M and S segments of Hantaan virus or portions of the M segment containing coding information only for Gl or G2. Our results suggest that immunization with Hantaan virus proteins produced by either recombinant baculoviruses or vaccinia viruses can elicit antibodies and protect animals from infection with Hantaan virus and that Hantaan virus subunit vaccines may provide efficacious alternatives to killed virus vaccines.
MATERIALS AND METHODS
Viruses, cells, and media. Autographa californica nuclear polyhedrosis virus (AcNPV) was kindly supplied by Max Summers. Spodopterafrugiperda (SF-9) (ATCC CRL 1711) cells were purchased from the American Type Culture Collection, Rockville, Md., and were maintained as suspension cultures in TNM-FH medium (24) (14) . Digestion with BglIl generated a restriction fragment of approximately 3.5 kilobases which contained the entire coding region for the Hantaan virus Gi and G2 envelope glycoproteins. The cDNA was cloned into the BamHI site of the baculovirus transfer vectors pAcYM1 (13) or pVL941 (10) . For subcloning into the SmaI site of the vaccinia virus transfer vector pSC11 (11), the DNA was treated with the large (Klenow) fragment of DNA polymerase I to produce blunt ends. Restriction fragments containing only Gl-coding information (BglII-DraI) or only G2-coding information (HpaII-BgIII) were similarly treated to produce blunt ends and were cloned into the BamHI site of pAcYM1 or the SmaI site of pSC11 after treatment of the linearized plasmids with the Klenow fragment. cDNA representing the S genome segment of Hantaan virus, which had been previously cloned into pGeml (Promega Biotec, Madison, Wis.) (19) , was excised by AccI digestion, which cleaves six nucleotides from the 5' end of the message sense Hantaan S cDNA and within the multiple cloning region of pGeml beyond the 3' terminus of the Hantaan virus cDNA insert. The restricted DNA was treated with Klenow fragment and cloned into the SmaI site of pSC11. Construction of the transfer vector pACYM1-Hantaan S was previously described (22 Hantaan virus S segment cDNA and AcNPV has been described previously (22 64, 1990 on October 28, 2017 by guest http://jvi.asm.org/ Downloaded from (Calbiochem-Behring, La Jolla, Calif.), and proteins were immune precipitated with polyclonal antibodies or with MAb as previously described (21) . SF-9 cells were infected with recombinant baculoviruses and radiolabeled, and proteins were immune precipitated from cell lysates in the same manner, except that the labeling medium was cysteine-free Grace's insect medium (GIBCO) supplemented with 2% fetal bovine serum. To perform polyacrylamide gel electrophoresis (PAGE), immune-precipitated, expressed proteins were subjected to discontinuous electrophoresis on 12.5% acrylamide-N,N'-diallytartardiamide gels as previously described (17) . cell spot slides (1, 16) .
Animal immunizations and Hantaan virus challenge. For immunogenicity studies, groups of 10 CB6F1/J mice were inoculated by tail scarification with 10,ul (approximately 106 PFU) of each recombinant vaccinia virus. Animals were bled 21 days after immunization, and serum antibody titers to vaccinia virus and Hantaan virus antigen were measured by enzyme-linked immunosorbent assay (ELISA), employing reaction conditions essentially as previously described (20) . ELISA antigen consisted of vaccinia virus or Hantaan virus grown in Vero E6 cells and purified by sedimentation in sucrose gradients (17) . A second inoculation with the same amount of each virus was administered i.p. 50 days after the first inoculation to half of the mice in each group. After 21 days, all mice were again bled (including the five animals that had received only one inoculation), and serum antibody titers were measured by ELISA.
To assess protection as well as immunogenicity, 8-to 10-week-old outbred female Syrian hamsters (Charles River) were immunized with candidate recombinant vaccine preparations as follows. Primary infections with recombinant vaccinia viruses were accomplished by scarification of the skin in the axillary region with a bifurcated needle and the subsequent addition of 25 ,ul of virus suspensions containing approximately 109 PFU per ml. Booster injections of recombinant vaccinia viruses were administered 28 days after the primary immunization by'i.p. injection of 0.2 ml of the identical viruses diluted 1:10 in sterile PBS. 'Recombinant baculovirus-infected SF-9 cells were pelleted by low-speed centrifugation, washed once in PBS, and, after a second centrifugation, resuspended in PBS to a concentration of 108 cells per ml. Cells were disrupted by freezing at -70°C and thawing at 37°C, and the resultant suspensions were injected i.m. (0.1 ml into each rear leg). Booster injections were given at 28 days and were identical to the primary injections. Animals were bled by cardiac puncture under anesthesia, and serum antibody responses were measured 1 day before challenge by IFAT (1) and PRNT on Vero E6 monolayers (16) (21), the recombinant expressing only Gi was constructed such that the potential intergenic region between Gl and G2 as well as coding information for the amino-terminal portion of G2 (211 amino acids) were included to allow cleavage at the G1-G2 junction (Fig. 1) . For preparation of a recombinant expressing only G2, a restriction fragment containing all of the G2-coding sequences plus 33 amino acids prior to the amino terminus of G2 was inserted into the transfer vectors. The additional nucleotide sequences included an in-frame ATG located 17 codons before the start of G2, which served as a translation initiation codon (Fig. 1) .
Expression of Hantaan virus proteins by recombinant baculoviruses. Expression of the complete M segment of Hantaan virus by AcNPV resulted in proteins indistinguishable from authentic Hantaan virus Gl and G2 by immune precipitation and PAGE (Fig. 2) . Although insect cells have slightly different glycosylation properties than mammalian cells, any differences in the carbohydrate components of the expressed proteins compared with the authentic proteins (18) were not evident by their electrophoretic migrations.
As previously reported (12), differences in transfer vectors can result in very different levels of foreign gene expression by recombinant baculoviruses. Therefore, we used two different transfer vectors reported to yield high levels of expression, pAcYM1 (13) and pVL941 (10) , to construct recombinants expressing the complete M segment of Hantaan virus. Similar levels of Gl and G2 appeared to be produced by the two resultant recombinant viruses, and the recombinant prepared by using the pAcYM1 transfer vector was used in all subsequent experiments.
Expression of gene regions encoding only Gl or G2 similarly resulted in proteins analogous to authentic Gl and G2 (Fig. 2) . Although recombinants expressing Gl also had coding information for the first 211 amino acids of G2 and thus could potentially produce a truncated G2 protein of approximately 23,000 daltons, no corresponding polypeptide could be detected by PAGE, suggesting that the partial G2 protein, if it was made at all, was unstable or was not recognized by the antibodies used for immune precipitation. As previously described (22) , recombinants containing coding information from the S genome segment of Hantaan virus produced large amounts of N, which could be immune precipitated with Hantaan virus-specific antibodies. (14) . Expression of the S segment of Hantaan virus similarly generated a protein identical to N by PAGE (Fig.  2) ; however, the level of expression observed was quite low as compared with that of the M segment and was considerably lower than could be achieved in the baculovirus system. With Connaught strain recombinants, immune precipitation of expressed proteins from Vero E6 cell lysates coinfected with the three vaccinia virus recombinants which individually express Gi-, G2-, Gl and G2 but not with those expressing only G2 or N or with uninfected cell controls. Similarly, the anti-G2 MAb reacted only with cells infected with recombinants expressing G2 or both Gl and G2. These data indicated that at least the antigenic sites defined by these MAb were conserved on the expressed proteins.
Immunogenicity of the expressed proteins. Sera from mice inoculated once or twice with live recombinant vaccinia viruses were evaluated by ELISA for the presence of antibodies to both vaccinia and to Hantaan virus antigens. Antibody titers of individual animals to vaccinia virus measured at 3 and 10 weeks after the initial immunization indicated that all animals were infected with the recombinant viruses (data not shown). Pooled sera, which reflected results obtained with individual samples, are displayed in Table 1 . Antibody responses to Hantaan virus were detected 3 weeks after immunization with sera from animals immunized with all recombinants except Connaught G2, Connaught S, and WR S. The antibody titers observed 10 weeks after immunization were higher in all groups except those animals immunized with the S segment recombinants. Animals that received a second immunization with the recombinant viruses displayed higher antibody titers both to vaccinia virus and to Hantaan virus, again with the exception of the S segment recombinants. Because the animals immunized with the S segment recombinants displayed titers to vaccinia virus that were comparable to all other recombinants, the relatively low S segment expression observed with these viruses is probably responsible for their low-titer responses. In these studies, it was not possible to determine whether there were quantitative differences in the antibody responses elicited by the WR versus the Connaught strain recombinants, because the initial immunizing doses were not the same. However, in separate experiments in which the same amounts of infectious Connaught or WR strain recombinant vaccinia viruses were administered, mice receiving the more virulent WR strain viruses developed slightly higher and more rapid antibody responses, both to vaccinia virus and to Hantaan virus (data not shown).
To (22) , as compared with that produced by the recombinant vaccinia virus, provided a greater immunizing antigen dose. Any suggestion that the recombinants induce protective immune mechanisms other than neutralization (e.g., a cell-mediated response) must await further investigation.
In order to confirm our initial observations that the absence of antigen in the lungs of hamsters and our inability to detect antibodies by IFAT after challenge indicated protection, additional groups of hamsters (five per group) were immunized either once or twice with the baculovirus recombinants producing G1 and G2, G1 only, G2 only or N, or with the Connaught and WR strain vaccinia virus recombinants expressing both Gl and G2. Selected sera from each group were used for immune precipitation of authentic Hantaan virus proteins. The sera selected for study represented those within each group which were protected from challenge and those which remained susceptible to infection on the basis of our established criteria for estimating infection, i.e., the best and worst protective responses from each group. Animals that did not become infected should possess antibodies only to the expressed protein(s) with which they were immunized both before and after challenge, but animals that did become infected should exhibit demonstrable antibodies both to the protein(s) with which they were immunized before challenge as well as all three Hantaan virus structural proteins after challenge. In these experiments, all animals immunized with preparations of recombinant baculovirus-infected cells expressing both Gl and G2 genes appeared to be protected from infection; i.e., no antigen was apparent in lungs and there was no IFAT-detectable, Hantaan virus-specific antibody after challenge. Sera from hamsters receiving either one or two immunizations with these recombinant preparations had antibodies to Gl and G2 both before and after challenge, but not to N, confirming that the animals were not infected with Hantaan virus (Fig. 4A , lanes +M-1°and +M-2°). The predominant response appeared to be to G2. In contrast, most animals immunized once with preparations containing only baculovirus-expressed G2 did not appear to be protected, although the absence of antigen in the lungs of some animals suggested partial protection. Serum from an animal displaying no antigen in its lungs and antibodies only to G2 before challenge still exhibited immune precipitation of G1, G2, and N after challenge, indicating that the animal was infected with Hantaan virus (Fig. 4A, lane +G2-1° ). After two immunizations with the same preparation followed by challenge, the serum from an animal with no IFATdetectable antibody and no antigen in its lungs was found to immune precipitate only G2, thus the animal was protected (Fig. 4A, lane +G2-2° ). Two immunizations with the G2 recombinant vaccinia virus did not protect all animals from infection, however, as indicated by immune precipitation of all three Hantaan virus proteins by antibodies contained in the serum of an animal which did display antigen in its lungs despite two inoculations (Fig. 4A, lane -G2-2°) . Therefore, immunization with the individual G2 protein can protect some animals from infection but not as effectively as does immunization with expressed G1 and G2 together. In this study, the baculovirus-expressed Gl protein did not protect any animals from Hantaan virus infection, even after two immunizations (Fig. 4B) .
As observed in our previous experiments, two immunizations with preparations containing baculovirus-expressed N protected five out of five animals in that no Hantaan virus antigen could be detected in lungs and only N-specific antibodies were observed both before and after challenge, confirming that the N protein induced some sort of protective response in hamsters (Fig. 4B, lane +S-2°) . Also in agreement with our previous experiments, most animals immunized with either the Connaught or WR strain vaccinia virus recombinants expressing both G1 and G2 appeared to be protected. One animal immunized only once with a WR strain recombinant developed IFAT-detectable antibody to Hantaan virus after challenge but did not exhibit detectable antigen in its lungs. This animal had antibodies to G1, G2, and N after challenge, indicating that it was infected (Fig.  4C , lane -WR M-1°). All other sera examined contained antibodies only to the envelope glycoproteins both before and after challenge, supporting the conclusion that the recombinant proteins are able to induce an immune response in hamsters, which protects them from subsequent infection with Hantaan virus. 4 . PAGE of radiolabeled authentic Hantaan virus proteins immune precipitated with sera from hamsters immunized one time (10) The absence of HFRS-like disease in animals made it difficult to evaluate the ability of our potential vaccines to moderate disease; however, we were able to use a much more stringent test of experimental vaccine efficacy of the recombinant-expressed proteins, i.e., protection from Hantaan virus infection. As demonstrated by passive protection studies, a humoral response to either of the envelope glycoproteins was sufficient to protect against challenge, suggesting that immunization with expressed Gl or G2 proteins might elicit a protective immune response. However, we found that immunization with recombinants expressing the entire M segment, i.e., both Gl and G2, was much more effective at eliciting anti-Hantaan virus antibodies and protecting animals from Hantaan virus infection than immunization with those expressing either Gl or G2 genes separately. Whether this is due to an additive effect of antibodies to both proteins or to some other reason, such as an interaction of the two proteins which results in the formation or stabilization of conformationally dependent antigenic sites, was not resolved. Previous reports indicated that a cell-mediated response to Hantaan virus may also be involved in protection, but the Hantaan virus component(s) eliciting the response was not identified (2, 3) . In our studies, the ability of expressed N to protect animals from Hantaan virus challenge suggests that this protein can elicit a nonneutralizing, perhaps cell-mediated, protective immune response. Although there are previous examples of cell-mediated responses to internal viral antigens protecting animals from lethal challenge (8), our results were somewhat surprising in that virus infection was apparently prevented, as determined by the absence of detectable antibodies to any viral protein other than N following challenge. Additional information is required to define the important aspects of immunity to Hantaan virus; however, our data suggest that whatever the mechanism(s), our recombinant-expressed proteins are clearly capable of inducing a response that can protect animals from infection with Hantaan virus.
One goal of studies such as ours is the development of a vaccine to prevent HFRS. Although both the baculovirus and vaccinia virus expression systems yielded products effective in inducing immune responses in animals, each has advantages and disadvantages for use in the development of a vaccine suitable for humans. Recombinant vaccinia viruses offer the advantages of a live virus vaccine without the danger of reversion to the virulent form of the virus. The major disadvantage of a recombinant vaccinia virus vaccine is that it is an infectious agent and, therefore, could cause vaccine-related complications (albeit rarely), such as those observed during its use as a smallpox vaccine. Unlike vaccinia virus and Hantaan virus, baculoviruses cannot infect mammalian cells, so a vaccine developed from recombinant AcNPV offers the advantages of a traditional inactivated vaccine, without the potential risk of incomplete inactivation. Furthermore, production of such a vaccine could be accomplished safely under minimal containment conditions. Several disadvantages to a baculovirus-derived vaccine also stem from its ability to replicate only in insect 
